Intramuscular human interferon-beta injections in treatment of condylomata acuminata

Lancet. 1984 May 12;1(8385):1038-42. doi: 10.1016/s0140-6736(84)91450-8.

Abstract

A two-part study was done to assess the value of human fibroblast interferon (IFN-beta) in the treatment of condylomata acuminata. The first part was an open study of different IFN-beta preparations, which showed that intramuscular injection was the most suitable mode of administration of IFN-beta. In the double-blind placebo section 22 patients were given injections of 2 X 10(6) units IFN-beta or placebo for 10 consecutive days and followed up for 3 months. In 9 of the 11 in the IFN-beta group and 2 in the placebo group lesions disappeared from about 5 weeks after completion of the course of injections. After 3 months 8 of the non-responders were given a course of IFN-beta and all responded to treatment. None of those who had responded has had a recurrence, the disease-free period now being 12 months. Changes in (2'-5')oligo A synthetase levels in white blood cells confirm that intramuscular injections of IFN-beta produce a systemic response.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2',5'-Oligoadenylate Synthetase / blood
  • Adolescent
  • Adult
  • Animals
  • Clinical Trials as Topic
  • Condylomata Acuminata / therapy*
  • Double-Blind Method
  • Female
  • Genital Neoplasms, Female / therapy*
  • Genital Neoplasms, Male / therapy*
  • Humans
  • Injections, Intramuscular
  • Interferon Type I / administration & dosage*
  • Leukocytes / enzymology
  • Male
  • Papillomaviridae / growth & development
  • Random Allocation
  • Tumor Virus Infections / therapy
  • Virus Replication / drug effects

Substances

  • Interferon Type I
  • 2',5'-Oligoadenylate Synthetase